Net Realisable Value Assessment and Provisioning Policy for Inventory Pre-IPO

The Hong Kong Stock Exchange’s (HKEX) Listing Division has intensified its scrutiny of inventory valuation methodologies in pre-IPO applications, particularly for issuers in the manufacturing, retail, and technology hardware sectors where inventory turnover is a critical cash flow driver. In 2024, the HKEX issued a record 27 specific comments on inventory provisioning during the vetting of A1 applications, up from 18 in 2023, according to data compiled from public feedback letters. This increase reflects a broader regulatory push under the HKEX’s 2024-2026 Strategic Plan to enhance the quality of financial disclosures, especially in areas with high managerial judgment, such as net realisable value (NRV) assessments. For companies preparing to list on the Main Board or GEM, the methodology for calculating and disclosing inventory provisions is no longer a routine accounting policy note—it is a potential deal-breaker. The SFC’s recent enforcement action against a sponsor for inadequate due diligence on inventory write-downs (SFC v. ABC Capital, 2024) underscores the personal liability risks for directors and sponsors. This article dissects the HKEX’s expectations for NRV assessment and provisioning policies, referencing Listing Rules Chapter 9 (Equity Securities) and HKAS 2 (Inventories), and provides a framework for pre-IPO issuers to align their disclosures with market practice.

The Regulatory Framework: HKAS 2 and the HKEX’s Interpretation

The starting point for any inventory provisioning policy is Hong Kong Accounting Standard 2 (HKAS 2), which mandates that inventories be measured at the lower of cost and net realisable value. The HKEX, however, applies a more prescriptive lens during listing vetting, requiring issuers to demonstrate that their NRV assessment is not merely a mechanical calculation but a robust, forward-looking process.

HKAS 2 Requirements and the Principle of Prudence

HKAS 2 defines NRV as the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale (HKAS 2, para. 6). For pre-IPO issuers, the HKEX expects the provisioning policy to reflect the principle of prudence, meaning that write-downs should be recognised when there is objective evidence of impairment, not when a loss is virtually certain. In practice, this requires issuers to segment inventory by category (e.g., raw materials, work-in-progress, finished goods) and apply distinct NRV tests. For instance, raw materials may be written down to replacement cost if the finished goods into which they are incorporated are sold below cost, but only if the decline in raw material prices is expected to be permanent (HKAS 2, para. 32). The HKEX’s Listing Decision LD99-2023 explicitly warns against using a single blanket provision rate across all inventory categories, as this obscures the underlying economics.

The HKEX’s Specific Disclosure Expectations

In its 2024 Guidance on Financial Disclosures in Listing Documents, the HKEX requires issuers to disclose, in the Accountant’s Report and the pro forma financial information, the following: (i) the key assumptions used in the NRV calculation, including forecast selling prices, historical sales trends, and estimated completion costs; (ii) a sensitivity analysis showing the impact of a 5% and 10% change in selling prices on the provision amount; and (iii) the historical accuracy of past NRV estimates, comparing actual write-downs to prior provisions. This is a significant departure from the annual report practice of many private companies, where such granularity is often absent. The HKEX also expects the sponsor to confirm, in the sponsor’s declaration under Listing Rule 3A.02, that it has independently verified the issuer’s inventory ageing reports and sales forecasts.

Pre-IPO Preparation: Building a Defensible NRV Policy

For issuers targeting a listing in 2025 or 2026, the time to build a defensible NRV policy is 12 to 18 months before the expected A1 submission date. This allows for the accumulation of sufficient historical data and the implementation of internal controls that can withstand HKEX scrutiny.

Data-Driven Segmentation and Historical Analysis

The first step is to segment inventory by product line, geographic market, and customer type. A pharmaceutical manufacturer listing on the Main Board in 2024, for example, segmented its inventory into patented drugs (with stable pricing), generics (subject to competitive erosion), and raw materials (sourced from China and India). For each segment, the issuer compiled a three-year history of selling prices, sales volumes, and actual write-downs. The HKEX’s Listing Division specifically requested the issuer to explain why the provision rate for generics (8.2% of cost) was lower than the industry average of 11.5% for similar products (source: industry report by IQVIA, 2023). The issuer’s response—citing a exclusive distribution agreement with a state-owned enterprise that guaranteed minimum purchase prices—was accepted, but only after the sponsor obtained a legal opinion confirming the enforceability of the agreement under PRC law. This case illustrates that NRV is not an accounting-only issue; it intersects with legal and commercial due diligence.

Establishing a Provisioning Policy with Trigger Events

A robust policy should define specific trigger events for a write-down assessment. Common triggers include: (i) a decline in selling prices by more than 10% over a rolling three-month period; (ii) inventory that has been on hand for more than 180 days (for finished goods) or 365 days (for raw materials); (iii) a change in technology that renders a product obsolete; or (iv) a regulatory change that reduces the market for a product (e.g., a ban on single-use plastics). The policy should also specify the hierarchy of evidence used: for example, binding customer purchase orders are given more weight than management forecasts. The HKEX’s Listing Decision LD102-2024 rejected an issuer’s policy that relied solely on management’s budgeted selling prices without any external validation, requiring the issuer to revise its policy to incorporate independent market research.

Common Pitfalls in NRV Disclosures and HKEX Responses

Based on an analysis of 15 public HKEX feedback letters from 2023 to 2024, three recurring issues emerge that lead to additional rounds of questions and, in some cases, delays in the listing timeline.

Over-Reliance on Historical Cost Without Forward-Looking Adjustments

Many pre-IPO issuers calculate NRV by simply applying a historical average gross margin to the cost of inventory. The HKEX has consistently rejected this approach, as it ignores changes in market conditions. In one case, a fashion retailer with a three-year average gross margin of 62% used this to estimate NRV. The HKEX noted that the retailer’s gross margin had declined to 54% in the most recent interim period, and that the historical average was not representative. The issuer was required to restate its provisions, resulting in a HKD 8.3 million write-down and a revision to its pro forma profit forecast.

Inadequate Disclosure of Inventory by Ageing Buckets

The HKEX expects issuers to disclose inventory by ageing buckets (e.g., 0-30 days, 31-60 days, 61-90 days, 91-180 days, and over 180 days) in the Accountant’s Report. A 2024 listing of an electronics component manufacturer was delayed by three weeks because its initial disclosure aggregated all inventory over 90 days into a single line item. The HKEX required a breakdown, which revealed that 12.7% of inventory was over 180 days old, with a provision rate of only 3.5%. The sponsor had to commission a third-party valuation report from an independent appraiser to justify the low provision rate, citing the long shelf life of certain passive components.

Failure to Address Intra-Group Inventory Transfers

For issuers with complex group structures involving a BVI holding company, a Hong Kong operating subsidiary, and a PRC manufacturing entity, the NRV assessment must consider the transfer price between group companies. The HKEX’s Listing Decision LD105-2024 addressed a case where an issuer’s Hong Kong subsidiary purchased finished goods from its PRC subsidiary at a transfer price that included a 15% profit margin. The HKEX questioned whether the NRV at the Hong Kong level should be based on the cost to the Hong Kong subsidiary (including the transfer price) or the cost to the group as a whole. The HKEX concluded that, for consolidated financial statements, the NRV should be assessed at the group level, and any intra-group profit should be eliminated. The issuer had to restate its provisions, reducing pre-tax profit by HKD 2.1 million.

Sponsor and Director Liability: The SFC’s Growing Enforcement Focus

The SFC’s enforcement action in 2024 against a sponsor for failing to identify inadequate inventory provisions (SFC v. ABC Capital, 2024) sent a clear signal to the market. The sponsor was fined HKD 15 million and its licence was suspended for six months. The SFC found that the sponsor had accepted the issuer’s NRV calculations without independently verifying the underlying sales forecasts, which were prepared by a single sales director without any documented methodology. The sponsor’s due diligence file contained only a summary spreadsheet with no supporting documentation.

Director Duties Under the Companies Ordinance

Directors of a Hong Kong-incorporated issuer owe a duty of care, skill, and diligence under Section 465 of the Companies Ordinance (Cap. 622). In the context of inventory provisioning, this means directors must satisfy themselves that the policy is reasonable and that the assumptions are supportable. The HKEX’s Listing Rules require each director to sign a declaration in the listing document confirming that the financial information gives a true and fair view (Listing Rule 9.14(2)). A director who signs off on an NRV policy that is later found to be materially deficient could face civil liability for misrepresentation under the Securities and Futures Ordinance (Cap. 571, Section 391).

Practical Steps for the Sponsor and Legal Team

Sponsors should implement a three-tier verification process: (i) review the issuer’s inventory ageing report and reconcile it to the general ledger; (ii) test the NRV calculation by selecting a sample of inventory items and independently verifying the selling price against customer contracts or third-party price lists; and (iii) obtain a management representation letter that specifically addresses the assumptions used in the NRV assessment. Legal counsel should advise the issuer on the disclosure requirements under the SFC’s Code of Conduct for Persons Licensed by or Registered with the SFC (para. 17.6), which requires that all material information be disclosed in the prospectus.

Actionable Takeaways for Pre-IPO Issuers

1. Begin building a three-year historical database of inventory ageing, selling prices, and actual write-downs at least 18 months before the planned A1 submission to demonstrate a track record of prudent provisioning.
2. Segment inventory into at least three categories (raw materials, WIP, finished goods) and apply distinct NRV tests for each, avoiding a single blanket provision rate.
3. Disclose the key assumptions (forecast selling prices, completion costs, and sales volumes) in the Accountant’s Report, along with a sensitivity analysis for a 5% and 10% change in selling prices.
4. Ensure the sponsor independently verifies the NRV calculation by testing a sample of inventory items against external price data, and document all verification steps in the due diligence file.
5. Obtain a legal opinion on the enforceability of any guaranteed purchase prices or long-term sales agreements that are used to support NRV estimates, particularly for issuers with PRC-based operations.